Neoplasms

Symptoms and General Pathology

All Conditions

Digestive System Diseases

Neoplasm Metastasis

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

All Drugs and Chemicals

Liver Extracts

MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.

DCE MRI

Kyung Won Kim, M.D.

Advanced MRI (Magnetic Resonance Imaging) technique called DCE (Dynamic Contrast Enhanced) and DWI MRI can provide valuable information regarding tumor biology and response to treatment through various parameters. Validating stability of these parameters will further establish robustness and reliability of these promising biomarkers.

Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body

Repeatability coefficient of Ktrans, Kep, Ve, IAUGC60, and ADC value of the index tumor will be measured.

Bracco Diagnostics, Inc

Asan Medical Center

Assistance Professor

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Within one week prior to resection two \[18F\]F-AraG PET-scans will be performed.

\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.

[18F]F-AraG PET-scan

I. Bahce, MD, PhD

I Bahce, MD, PhD

\[18F\]F-AraG is a promising tracer to image activated T-cells with positron emission tomography (PET). The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of this novel tracer by performing a full kinetic modelling, assess test-retest (TRT) variability and to correlate the tumor tracer uptake with the pathological assessment.

The efficacy of immunotherapy and patient selection for combinatorial immunotherapy strategies would greatly improve if the tumor microenvironment (TME) could be characterized more accurately. Positron emission tomography (PET) using tracers that target immune cell subsets may provide a non-invasive means to immune profile the TME. Imaging T-cells can help in identifying 'hot' tumors, or parts of the tumor mass that have high concentrations of tumor infiltrating T-cells and also provide information on its activation.

A promising tracer to image activated T-cells is \[18F\]F-AraG. Based on the hypothesis that \[18F\]F-AraG will accumulate in activated T-cells, it is expected that \[18F\]F-AraG and PET will enable to (reproducibly) identify tumors and tumor areas with high concentrations of tumor infiltrating activated T-cells on pathological assessment. In the ATTAIN trial this \[18F\]F-AraG uptake in tumor lesions and healthy organs is explored by full kinetic modelling.

[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.

A Clinical Imaging Study Using [18F]F-AraG PET to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.

To explore the \[18F\]F-AraG PET uptake in tumor, lymph nodes and spleen with the immune profile of peripheral blood mononuclear cells (PBMC).

To perform full kinetic modeling of \[18F\]F-AraG for the uptake in tumor lesions and healthy organs (e.g. spleen) by exploring different kinetic models and outcome measures as well as its test-retest (TRT) variability to guide the selection of an optimal PET pharmacokinetic model.

To correlate the relationship between the tumor uptake of \[18F\]F-AraG and the number of CD8 T-cells amongst others as measured by Immunohistochemistry (IHC) and gene expression.

To correlate the \[18F\]-FDG PET uptake with uptake derived from \[18F\]F-AraG PET

Amsterdam UMC, location VUmc

dr. I. Bahce

Skin and Connective Tissue Diseases

Breast Neoplasms

Neoplastic Processes

Beathe Sitter, PhD

Develop and optimize protocols for whole body MRI for detection of metastases. Evaluate diagnostic accuracy through application of optimized protocols for screening of cancer patients.

Whole-body MRI for the Detection of Metastasis

Number of skeleton metastasis will be assessed at the regular clinical follow-up of breast cancer patients with metastatic disease

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body	NCT02201797	Metastatic Live...	DCE MRI	18 Years -	Asan Medical Center
[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.	NCT05157659	Non-Small Cell ...	[18F]F-AraG PET...	18 Years -	Amsterdam UMC, location VUmc
Whole-body MRI for the Detection of Metastasis	NCT02183597	Breast Cancer Metastases		18 Years - 95 Years	Norwegian University of Science and Technology
Whole-body MRI for the Detection of Metastasis	NCT02183597	Breast Cancer Metastases		18 Years - 95 Years	Norwegian University of Science and Technology
[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.	NCT05157659	Non-Small Cell ...	[18F]F-AraG PET...	18 Years -	Amsterdam UMC, location VUmc

Spots Global Cancer Trial Database for reproducibility of results